Ultra-Processed Foods Linked to Early Signs of Parkinson's Disease
Ultra-processed foods are associated with a rogues' gallery of health problems, including elevated risk for obesity, dementia, type 2 diabetes, and heart disease.
Yet despite experts' warnings, ultra-processed foods are satisfying, cheap, and easy, making them popular across much of the world. In the US, more than half of all calories adults consume at home now come from ultra-processed foods.
As researchers race to keep up, the list of suspected risks continues to grow.
According to an international team of researchers who analyzed decades of records from tens of thousands of health workers, people who eat a lot of ultra-processed foods are more likely to have early signs of Parkinson's disease than those who don't.
This does not prove causation, but it does reveal a noteworthy association, especially in the broader context of health concerns related to ultra-processed foods. It also adds to mounting evidence that diet is key to brain health.
"Eating a healthy diet is crucial as it has been associated with a lower risk of neurodegenerative diseases, and the dietary choices we make today can significantly influence our brain health in the future," says co-author Xiang Gao, a nutritional epidemiologist with the Institute of Nutrition at Fudan University in Shanghai.
In the new study, researchers focused on signs of Parkinson's disease that appear before more specific symptoms develop, which can include body pain, constipation, depressive symptoms, excessive daytime sleepiness, and an impaired sense of smell. At this stage, while patients may not have characteristic features of the disease, neurodegeneration may have already begun.
"There's growing evidence that diet might influence the development of Parkinson's disease. Our research shows that eating too much processed food, like sugary sodas and packaged snacks, might be speeding up early signs of Parkinson's disease," Gao says.
The researchers conducted a longitudinal analysis using data from the Nurses' Health Study and the Health Professionals Follow-Up Study, letting them track details about the diet and health of nearly 43,000 people for up to 26 years.
This sample included men and women with an average age of 48 years, who had no history of Parkinson's disease. The subjects had received regular medical exams and completed biennial health questionnaires, which Gao and his colleagues reviewed for early signs of Parkinson's disease.
Subjects also submitted responses to surveys at two- to four-year intervals, offering insight into their dietary habits. Researchers used this to estimate each subject's average daily ingestion of ultra-processed foods, as defined by the Nova classification system for food processing.
The study covered several types of ultra-processed foods, including sauces, spreads, or condiments; artificially or sugar-sweetened beverages; packaged savory snacks; packaged sweets; snacks or desserts; yogurt or dairy-based desserts; and animal-based products.
Subjects were split into five groups based on their consumption of ultra-processed foods. Those in the highest group ate 11 or more servings per day on average, while the lowest group averaged fewer than three daily servings.
The researchers adjusted for factors such as age, alcohol intake, body mass index, caffeine intake, physical activity, and tobacco smoking, among others.
Subjects who ate 11 or more daily servings of ultra-processed foods were 2.5 times likelier to have at least three early signs of Parkinson's disease compared with subjects who ate fewer than three servings per day, the authors report.
Higher consumption of ultra-processed foods was linked with increased risk of almost all early signs of Parkinson's disease used in this study, they found, with the exception of constipation.
There are some important caveats to these findings. They show an association between ultra-processed foods and increased risk for early signs of Parkinson's disease, but more research is needed to clarify the nature of the relationship.
The focus on early signs of Parkinson's disease also involves some ambiguity, as the authors acknowledge, since these are potential hints of the condition rather than definitive indicators.
Many of the early signs – body pain, for example, or daytime sleepiness – are common as people age and don't necessarily herald Parkinson's disease.
All of these features considered in composite, however, are "strongly predictive" of subsequent Parkinson's disease diagnoses, the researchers write.
"Choosing to eat fewer processed foods and more whole, nutritious foods could be a good strategy for maintaining brain health," Gao says.
"More studies are needed to confirm our finding that eating less processed food may slow down the earliest signs of Parkinson's disease."
The study was published in Neurology.
AI Discovers Suspected Trigger of Alzheimer's, And Maybe a Treatment
One Stage of Sleep Seems Critical For Reducing Risk of Dementia
World First: US Baby Treated With Personalized CRISPR Gene-Editing
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Space Force's first next-gen missile warning launch pushed to 2026
Despite expectations for an on-time satellite delivery, the Space Force has opted to delay the launch of its first Next-Generation Overhead Persistent Infrared spacecraft until at least next spring due to high demand for launch services. The satellite is one of two Lockheed Martin-built spacecraft designed to provide early missile-warning capabilities from geosynchronous Earth orbit as part of the Next-Gen OPIR GEO program. According to a new report from the Government Accountability Office, the first satellite will now stay on the ground until at least March of 2026 'due to a crowded 2025 launch manifest.' GAO has long warned that the program's schedule was likely too ambitious due to the technology requirements for its mission payload, and the agency predicted its launch would likely be delayed by at least one year. Those projections could prove true, but perhaps for more nuanced reasons. RTX, the program's payload supplier, faced development challenges that delayed its delivery by 13 months to August 2024. While that slowdown consumed most of the program's margin, the satellite has since progressed well through its testing milestones. The service now anticipates the spacecraft will be delivered by September. That means it could have flown this year had there been room in the launch manifest. GAO notes in its report, released today, that despite those successes — and because of the lack of schedule margin — the program still risks further delay if any issues arise during final integration. 'The program has no buffer in its schedule to first launch; any payload and space vehicle integration delays will likely result in launch delays and program cost increases,' the watchdog agency said. Next-Gen OPIR is part of a larger multi-orbit strategy to provide missile-warning and tracking capabilities from space. Along with the two GEO satellites, the Space Force has contracted with Northrop Grumman to build two polar-orbiting spacecraft as part of Next-Gen-OPIR. These four satellites will eventually replace the existing Space-Based Infrared System. The two GEO spacecraft are expected to cost $9.5 billion, and the polar satellites have a total cost estimate of $5.9 billion. Separately, the Space Development Agency is leading an effort to develop a missile-tracking constellation in low Earth orbit made up of hundreds of small satellites. And the Space Force's primary acquisition arm, Space Systems Command, is spearheading a medium Earth orbit constellation. GAO's report evaluated progress on the two Next-Gen OPIR Polar spacecraft, finding the program is on track for delivery and launch in 2028 and is meeting its schedule for various program reviews. The report notes that the polar satellites are integrating a modified version of the same mission payload as the GEO spacecraft, which could introduce schedule risk when the program reaches the integration phase. The report notes that the program approved a cybersecurity strategy last year and plans to run a series of tests this year and a full system assessment in 2027.
Los Angeles Times
4 hours ago
- Los Angeles Times
Parkinson's Disease: What We Know and Where Treatment Is Headed
Parkinson's disease (PD) is more than a movement disorder—it's a neurological condition that reshapes the lives of patients and families. Parkinson's affects both motor and non-motor functions so its impact is broad and multifaceted. While tremors and stiffness may be the most visible signs, PD also brings a wide range of symptoms that impact thinking, mood and overall functioning. Common symptoms are bradykinesia, rigidity, tremor, postural instability, sleep disturbances and mood changes. As science digs deeper into this condition, hope grows for more precise, effective and compassionate care. Parkinson's disease is defined by the gradual loss of dopamine producing neurons in a part of the brain called the substantia nigra. This dopamine deficiency disrupts the brain circuits responsible for smooth and coordinated movements, leading to hallmark motor symptoms: resting tremor, muscle rigidity, slowness of movement (bradykinesia) and postural instability [1] [3] [5]. These are the most common Parkinson's disease symptoms targeted by treatment. The hallmark motor symptoms encompass a range of movement symptoms and movement related symptoms that affect daily functioning. Postural instability often results in balance problems making coordination and stability difficult for patients. In addition to resting tremor, muscle rigidity, slowness of movement (bradykinesia) and postural instability, other motor symptoms such as freezing of gait and difficulty with fine motor tasks may also occur. Collectively these are referred to as PD symptoms, the clinical features of Parkinson's disease. But PD isn't just about what the body can or can't do—it's also about what the brain feels. Long before a tremor appears many patients experience non-motor symptoms: Parkinson's symptoms, both motor and non-motor, can develop gradually and vary significantly between individuals. These symptoms can be easy to overlook or misattribute, often delaying diagnosis. According to a 2008 review, clinicians rely on a detailed medical history and physical examination to distinguish PD from other parkinsonian syndromes [1], while a 2020 JAMA review emphasizes the role of dopamine transporter (DAT) imaging and clinical expertise in diagnosis and staging [5]. Parkinson's is diagnosed primarily through evaluation of medical history and clinical examination, as there is no definitive blood test or brain scan for confirmation. So, what causes Parkinson's disease? The short answer: it's complicated. Most cases are considered idiopathic—meaning no single cause is identified—but multiple factors seem to converge. Both genetic and environmental factors are recognized as major contributors to the development of Parkinson's disease. Genetic contributions are increasingly recognized, with mutations in genes like LRRK2, PARK7 and SNCA playing a role [2]. Genetic mutations in these and other genes can influence disease development, sometimes interacting with environmental exposures. But genes don't tell the whole story. Environmental exposures, such as pesticide use or heavy metals, also contribute, especially in individuals with underlying vulnerabilities. At the cellular level PD is defined by several overlapping pathological processes: The loss of dopamine producing neurons in the substantia nigra involves the degeneration and death of specific brain cells and nerve cells which underlies the motor and non-motor symptoms of Parkinson's disease. These mechanisms interact like a feedback loop—fueling one another and accelerating neurodegeneration. This complex interplay drives the disease process, shaping both the progression and development of Parkinson's disease. Parkinson's disease affects more than 10 million people worldwide, with incidence rising sharply with age—especially after 60 [11]. Most Parkinson's disease cases are idiopathic and occur in older adults, with the majority of diagnoses in people over 60. However, early onset cases, known as early onset PD, can develop before age 50 and may differ in disease progression, diagnosis and treatment compared to typical cases. Men are more frequently affected than women, and rural living, well water exposure and pesticide contact are established risk factors. On the other hand, researchers have also identified protective factors. Regular caffeine consumption, moderate nicotine exposure and consistent physical activity may lower PD risk. Though not fully understood, these factors may influence inflammation, neuroplasticity or dopamine metabolism. There's no single test for Parkinson's, which makes early and accurate diagnosis a clinical challenge. Physicians typically rely on: In advanced diagnostic settings a spinal tap (lumbar puncture) may be performed to collect spinal fluid for biomarker analysis, such as detecting abnormal alpha-synuclein proteins. New frontiers are expanding diagnostic accuracy. Machine learning algorithms are being trained to analyze voice patterns, gait dynamics and digital biomarkers. AI-enhanced diagnostics and bioinformatics platforms are also being developed to detect early inflammatory signals before motor symptoms emerge [10]. Autonomic testing, including monitoring for blood pressure changes, may be used to assess non-motor symptoms. Distinguishing Parkinson's disease from other syndromes is crucial, with multiple system atrophy being an important differential diagnosis due to overlapping symptoms but differing disease progression and treatment responses. While there's no cure for PD, treatment can significantly improve quality of life. The primary goal of therapy is to manage symptoms and help patients maintain independence. Medications: Medication is different from surgery and should be discussed with a doctor. Dopaminergic medications can cause orthostatic hypotension and low blood pressure so monitoring is important. Non-medication is equally important: PD can also affect mood, behavior and cognition. Managing neuropsychiatric symptoms like depression or hallucinations requires a nuanced approach, including SSRIs, atypical antipsychotics and cognitive behavioral therapy. The Parkinson's Foundation is a key player in advancing research and treatment for Parkinson's disease. As the disease progresses many patients develop cognitive impairment, from mild forgetfulness to full blown Parkinson's Disease Dementia (PDD). These symptoms can overlap with or mimic Dementia with Lewy Bodies (DLB) (also known as Lewy body dementia) and Progressive Supranuclear Palsy (PSP) and other disorders within the spectrum of atypical parkinsonism, so accurate diagnosis is critical. A 2025 study compared cognitive trajectories across these syndromes and emphasized the need for tailored care and better biomarkers to distinguish between them. Inflammation is no longer seen as just a consequence of PD—it may be the cause. Recent studies, including a 2025 paper using machine learning and bioinformatics, have identified new inflammatory markers that could help with early diagnosis [10]. Ongoing Parkinson's research is key to finding new biomarkers, better treatments and a are also finding potential therapeutic targets. For example, UPS10, a protein that blocks α-synuclein degradation, may be a way to stop disease progression [8]. And lipid metabolism pathways open up metabolic interventions. These therapeutic strategies aim to modify the disease process to slow or stop progression. This is driving personalized medicine where treatment is based on a patient's genetic, metabolic or inflammatory profile. And the average life expectancy for most people with PD is the same as the general population thanks to research and care. Parkinson's disease is still a challenge for patients, caregivers and clinicians. But it's also a global research effort to understand the onset, progression and treatment of the disease. As we understand the interplay of genetics, environment and inflammation the future of PD looks more precise and hopeful. Until then a multidisciplinary approach – medication, therapy and emotional support – is the foundation of good care. [1] Jankovic J. (2008). Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery, and psychiatry, 79(4), 368–376. [2] Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. Lancet (London, England), 386(9996), 896–912. [3] Marino, B. L. B., de Souza, L. R., Sousa, K. P. A., Ferreira, J. V., Padilha, E. C., da Silva, C. H. T. P., Taft, C. A., & Hage-Melim, L. I. S. (2020). Parkinson's Disease: A Review from [4] Pathophysiology to Treatment. Mini reviews in medicinal chemistry, 20(9), 754–767. [5] Balestrino, R., & Schapira, A. H. V. (2020). Parkinson disease. European journal of neurology, 27(1), 27–42. [6] Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323(6), 548–560. [7] Qin, B., Fu, Y., Raulin, A. C., Kong, S., Li, H., Liu, J., Liu, C., & Zhao, J. (2025). Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease. Chinese medical journal, 10.1097/CM9.0000000000003627. Advance online publication. [8] Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. Lancet (London, England), 397(10291), 2284–2303. [9] Anisimov, S., Takahashi, M., Kakihana, T., Katsuragi, Y., Sango, J., Abe, T., & Fujii, M. (2025). UPS10 inhibits the degradation of α-synuclein, a pathogenic factor associated with Parkinson's disease, by inhibiting chaperone-mediated autophagy. The Journal of biological chemistry, 110292. Advance online publication. [10] Halli-Tierney, A. D., Luker, J., & Carroll, D. G. (2020). Parkinson Disease. American family physician, 102(11), 679–691. [11] Li, Y., Jia, W., Chen, C., Chen, C., Chen, J., Yang, X., & Liu, P. (2025). Identification of biomarkers associated with inflammatory response in Parkinson's disease by bioinformatics and machine learning. PloS one, 20(5), e0320257. [12] Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 124(8), 901–905.
Business Wire
11 hours ago
- Business Wire
Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson's Disease Associated With GBA Mutations
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Capsida Biotherapeutics ('Capsida') today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class intravenously (IV) administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This is the second wholly owned clinical program developed by Capsida with a cleared IND. Both programs utilize a proprietary IV-delivered, blood brain barrier-crossing engineered capsid and proprietary cargo that is detargeted from off-target tissues, like liver and dorsal root ganglia (DRG). In addition, Capsida uses a proprietary manufacturing process and CAP-003 is manufactured in Capsida's state-of-the-art wholly owned Good Manufacturing Practice (GMP) facility. 'PD-GBA is an area of substantial unmet need given the lack of approved treatments that target GCase, which is the protein encoded by the GBA gene, and provide meaningful slowing or halting of disease progression,' said Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics. 'We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial for CAP-003 with the aim of dosing the first patient in the third quarter of this year.' About CAP-003 and the Phase 1/2 Clinical Trial In non-human primate (NHP) studies to date, a single IV infusion of CAP-003 resulted in dose-dependent increases in GCase activity in critical brain regions including the substantia nigra, frontal cortex, caudate nucleus, and putamen substantially above the established 30% efficacy threshold expected to restore enzyme activity levels back to normal in patients with PD-GBA. The NHP Good Laboratory Practices (GLP) toxicology study demonstrated a well-tolerated safety profile with no adverse histopathology. Capsida expects to dose the first patient in the Phase 1/2 clinical trial in the third quarter of this year. For more information about the Phase 1/2 clinical trial, please visit (NCT07011771). About Parkinson's disease associated with GBA mutations (PD-GBA) Mutations in GBA, the gene expressing the GCase enzyme, affect up to 15% of Parkinson's patients and are the most common genetic risk factor for PD. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to healthy individuals 1. There are no approved treatments that target GCase and there are no approved disease modifying treatments for PD. Other investigational treatments for PD-GBA have been limited by their inability to cross the blood-brain barrier and supplement GCase enzyme activity in sufficient quantities to overcome the deficit in patients and impact the disease. In an attempt to overcome these challenges, those treatments have required invasive direct brain or cerebrospinal fluid (CSF) administration, with limited results, and a significant burden for patients. About Capsida Biotherapeutics Capsida Biotherapeutics is a clinical-stage, fully integrated next-generation genetic medicines company. It has a central nervous system (CNS) pipeline consisting of disease-modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida's wholly owned pipeline includes its first-in-class investigational treatment for STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), CAP-002; and potential best-in-class investigational treatment for Parkinson's disease associated with GBA mutations (PD-GBA) CAP-003. Both have received FDA Investigational New Drug (IND) clearance to initiate clinical trials. Capsida's pipeline also includes a potential best-in-class treatment for Friedreich's ataxia (FA). In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at 1 Leyns, C. E, G. et al (2023). npj Parkinson's Disease, 74(9).
